Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
October 1, 2024
This is not only safer (less toxicity with nivo) but reduced disease progression or death by 52%.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
May 1, 2023
Pembro + ICE seems to be a compelling option in the 2L setting for transplant eligible cHL patients, however this is not yet in guidelines.
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma
May 1, 2023
Pembro + AVD for 1L treatment of cHL was associated with excellent responses, PFS and clearance of ctDNA. IO+chemo seems to be a growing trend in HL in various settings and theses response rates in non-Bleo regimens are very encouraging. The ongoing trial NCT05675410 comparing BV+AVD vs. Nivo+AVD should be a pivotal trial when complete.
